The invention provides a method for inhibiting the depletion of healthy tissue during CAR T cell therapy comprising administering a drug-molecule conjugate comprising a drug and a molecule to a subject receiving CAR T cell therapy, wherein the molecule binds to a CAR expressed on the surface of a T cell. The invention relates to binding of the conjugate to the CAR resulting in internalization of the conjugate into the cell and drug-mediated death of the cell.